187 related articles for article (PubMed ID: 15164984)
1. Interstitial infusion of IL13-PE38QQR in the rat brain stem.
Souweidane MM; Occhiogrosso G; Mark EB; Edgar MA
J Neurooncol; 2004 May; 67(3):287-93. PubMed ID: 15164984
[TBL] [Abstract][Full Text] [Related]
2. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.
Parney IF; Kunwar S; McDermott M; Berger M; Prados M; Cha S; Croteau D; Puri RK; Chang SM
J Neurosurg; 2005 Feb; 102(2):267-75. PubMed ID: 15739554
[TBL] [Abstract][Full Text] [Related]
3. Interstitial infusion of carmustine in the rat brain stem with systemic administration of O6-benzylguanine.
Souweidane MM; Occhiogrosso G; Mark EB; Edgar MA; Dunkel IJ
J Neurooncol; 2004 May; 67(3):319-26. PubMed ID: 15164987
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of convection-enhanced delivery of IL13-Pseudomonas toxin in children with diffuse intrinsic pontine glioma.
Heiss JD; Jamshidi A; Shah S; Martin S; Wolters PL; Argersinger DP; Warren KE; Lonser RR
J Neurosurg Pediatr; 2018 Dec; 23(3):333-342. PubMed ID: 30544335
[TBL] [Abstract][Full Text] [Related]
5. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft.
Husain SR; Puri RK
Blood; 2000 Jun; 95(11):3506-13. PubMed ID: 10828036
[TBL] [Abstract][Full Text] [Related]
7. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Kawakami K; Husain SR; Kawakami M; Puri RK
Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
[TBL] [Abstract][Full Text] [Related]
8. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies.
Kunwar S
Acta Neurochir Suppl; 2003; 88():105-11. PubMed ID: 14531568
[TBL] [Abstract][Full Text] [Related]
9. Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies.
Kunwar S; Chang SM; Prados MD; Berger MS; Sampson JH; Croteau D; Sherman JW; Grahn AY; Shu VS; Dul JL; Husain SR; Joshi BH; Pedain C; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E15. PubMed ID: 16709020
[TBL] [Abstract][Full Text] [Related]
10. Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin.
Murad GJ; Walbridge S; Morrison PF; Garmestani K; Degen JW; Brechbiel MW; Oldfield EH; Lonser RR
Clin Cancer Res; 2006 May; 12(10):3145-51. PubMed ID: 16707614
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin.
Maini A; Hillman G; Haas GP; Wang CY; Montecillo E; Hamzavi F; Pontes JE; Leland P; Pastan I; Debinski W; Puri RK
J Urol; 1997 Sep; 158(3 Pt 1):948-53. PubMed ID: 9258124
[TBL] [Abstract][Full Text] [Related]
12. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
13. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4.
Debinski W; Obiri NI; Pastan I; Puri RK
J Biol Chem; 1995 Jul; 270(28):16775-80. PubMed ID: 7622490
[TBL] [Abstract][Full Text] [Related]
14. Prolonged convection-enhanced delivery into the rat brainstem.
Occhiogrosso G; Edgar MA; Sandberg DI; Souweidane MM
Neurosurgery; 2003 Feb; 52(2):388-93; discussion 393-4. PubMed ID: 12535369
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of Cintredekin Besudotox (IL13-PE38QQR) in murine lung fibrosis is unaffected by immunity to Pseudomonas aeruginosa exotoxin A.
Rosada RS; Moreira AP; Frantz FG; Puri RK; Rahman A; Standiford TJ; Zárate-Bladés CR; Silva CL; Hogaboam CM
PLoS One; 2010 Jan; 5(1):e8721. PubMed ID: 20090941
[TBL] [Abstract][Full Text] [Related]
16. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
Kunwar S; Prados MD; Chang SM; Berger MS; Lang FF; Piepmeier JM; Sampson JH; Ram Z; Gutin PH; Gibbons RD; Aldape KD; Croteau DJ; Sherman JW; Puri RK;
J Clin Oncol; 2007 Mar; 25(7):837-44. PubMed ID: 17327604
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
18. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activity of a recombinant toxin, OLX-209, which targets the erbB-2 oncoprotein.
Fischer PH; Bird RE; Kasprzyk PG; King CR; Turner NA; Pastan I; Kihara A; Batra J
Adv Enzyme Regul; 1994; 34():119-28. PubMed ID: 7942269
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
